| Identification | More | [Name]
(R)-(-)-2-Amino-3-methyl-1-butanol | [CAS]
4276-09-9 | [Synonyms]
2-AMINO-3-METHYLBUTAN-1-OL
D-2-AMINO-3-METHYL-1-BUTANOL
D-VALINAL
(-)-D-VALINOL
D-(-)-VALINOL
D-VALINOL
(D)-VALINOL/(R)-(-)-2-AMINO-3-METHYL-1-BUTANOL
H-D-VAL-OL
(R)-(-)-2-AMINO-3-METHYL-1-BUTANOL
(R)-(+)-2-AMINO-3-METHYL-1-BUTANOL
(R)-2-AMINO-3-METHYL-1-BUTANOL
(R)-(-)-2-AMINO-3-METHYLBUTAN-1-OL
(R)-(-)-2-AMINO-3-METHYLBUTANOL
R-VALINOL
D-(-)-VALINOL 98%
(R)-(-)-Z-Amino-3-Methyl-1-Butanol
D-Val-ol
D-(-)-Valinol,98%
1-Butanol, 2-amino-3-methyl-, (2R)-
(R)-(-)-2-Amino-3-methyl-1-butanol | [EINECS(EC#)]
217-975-5 | [Molecular Formula]
C5H13NO | [MDL Number]
MFCD00064297 | [Molecular Weight]
103.16 | [MOL File]
4276-09-9.mol |
| Chemical Properties | Back Directory | [Appearance]
white to light yellow crystal powde | [Melting point ]
35-36 °C(lit.) | [alpha ]
-16.5 º (c=10, EtOH) | [Boiling point ]
189-190 °C(lit.) | [density ]
0.931 g/mL at 20 °C(lit.)
| [refractive index ]
n20/D 1.455
| [Fp ]
194 °F
| [storage temp. ]
2-8°C
| [form ]
Low Melting Crystals or Crystalline Mass | [pka]
12.82±0.10(Predicted) | [color ]
White to light yellow | [optical activity]
[α]20/D 16°, c = 10 in ethanol | [Sensitive ]
Air Sensitive | [BRN ]
1719138 | [InChIKey]
NWYYWIJOWOLJNR-YFKPBYRVSA-N | [CAS DataBase Reference]
4276-09-9(CAS DataBase Reference) | [Storage Precautions]
Air sensitive;Store under nitrogen |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36/37:Wear suitable protective clothing and gloves .
S36:Wear suitable protective clothing . | [WGK Germany ]
3
| [F ]
10-34 | [HS Code ]
29221990 |
| Hazard Information | Back Directory | [Chemical Properties]
white to light yellow crystal powde | [Uses]
D-Valinol is used as a reagent in the synthesis of the HIV type 1 integrase inhibitor Elvitegravir (E509000). D-Valinol is also used in the preparation of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally active GSK-3β inhibitors for Alzheimer''s disease. |
|
|